WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526083

CAS#: 93738-40-0

Description: Ralitoline is an anticonvulsant. Ralitoline has sodium channel blocking activities. The efficacy of this compound seems to be comparable or even better than that of conventional antiepileptics.

Price and Availability




Ralitoline is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 526083
Name: Ralitoline
CAS#: 93738-40-0
Chemical Formula: C13H13ClN2O2S
Exact Mass: 296.0386
Molecular Weight: 296.77
Elemental Analysis: C, 52.61; H, 4.42; Cl, 11.95; N, 9.44; O, 10.78; S, 10.80

Synonym: Ralitoline; GOE-4942; PD-117818; Ralitolina; CI-946; Ralitolinum.

IUPAC/Chemical Name: (Z)-N-(2-Chloro-6-methylphenyl)-(3-methyl-4-oxothiazolidine-2-ylidene)acetamide


InChi Code: InChI=1S/C13H13ClN2O2S/c1-8-4-3-5-9(14)13(8)15-10(17)6-12-16(2)11(18)7-19-12/h3-6H,7H2,1-2H3,(H,15,17)/b12-6-


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Dostal LA, Anderson JA. Developmental toxicity study in rats treated with the anticonvulsant, ralitoline. Teratology. 1995 Jan;51(1):11-9. PubMed PMID: 7597653.

2: Fischer W, Bodewei R, Satzinger G. Anticonvulsant and sodium channel blocking effects of ralitoline in different screening models. Naunyn Schmiedebergs Arch Pharmacol. 1992 Oct;346(4):442-52. PubMed PMID: 1331817.

3: Löscher W, von Hodenberg A, Nolting B, Fassbender CP, Taylor C. Ralitoline: a reevaluation of anticonvulsant profile and determination of "active" plasma concentrations in comparison with prototype antiepileptic drugs in mice. Epilepsia. 1991 Jul-Aug;32(4):560-8. PubMed PMID: 1868813.

4: Rock DM, McLean MJ, Macdonald RL, Catterall WA, Taylor CP. Ralitoline (CI-946) and CI-953 block sustained repetitive sodium action potentials in cultured mouse spinal cord neurons and displace batrachotoxinin A 20-alpha-benzoate binding in vitro. Epilepsy Res. 1991 Apr;8(3):197-203. PubMed PMID: 1651226.

5: Anhut H, Satzinger G, von Hodenberg A. Ralitoline. Epilepsy Res Suppl. 1991;3:141-5. Review. PubMed PMID: 1777070.

6: Wagner B, Strumpf G, Bartoszyk GD. Similar effects of ralitoline and phenytoin on papillary muscle action potentials: evidence for sodium antagonistic activity. Pharmacol Res Commun. 1987 Sep;19(9):591-6. PubMed PMID: 3432324.